Prostaglandin-Independent Inhibition of Ocular Vascular Permeability by a Platelet-Activating Factor Antagonist

Richard M. Rubin, John R. Samples, James (Jim) Rosenbaum

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Platelet-activating factor (PAF), a lipid mediator of inflammation, may markedly increase vascular permeability. We assessed the ability of the PAF antagonist SRI 63-441 to inhibit ocular vascular permeability induced by the intravenous injection of endotoxin or anterior chamber paracentesis. The PAF antagonist SRI 63-441 significantly blocked ocular vascular permeability following either intravenous endotoxin or anterior chamber paracentesis as determined by the reduction in accumulation of 70 000-molecularweight fluorescein isothiocyanate—conjugated dextran or serum proteins into the anterior chamber. SRI 63-441 did not reduce increases in aqueous humor prostaglandin E2 levels. The efficacy of the PAF antagonist was additive in combination with either topical indomethacin or topical corticosteroid. Combined therapy almost completely prevented increases in ocular vascular permeability. These data support the conclusion that multiple mediators contribute to ocular vascular permeability and that combinations of pharmacologic agents may be superior to a single drug.

Original languageEnglish (US)
Pages (from-to)1116-1120
Number of pages5
JournalArchives of Ophthalmology
Volume106
Issue number8
DOIs
StatePublished - 1988

Fingerprint

Platelet Activating Factor
Capillary Permeability
Prostaglandins
Anterior Chamber
Paracentesis
Endotoxins
Inflammation Mediators
Aqueous Humor
Dinoprostone
Intravenous Injections
Indomethacin
Blood Proteins
Adrenal Cortex Hormones
Lipids
Pharmaceutical Preparations
SRI 63-441

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Prostaglandin-Independent Inhibition of Ocular Vascular Permeability by a Platelet-Activating Factor Antagonist. / Rubin, Richard M.; Samples, John R.; Rosenbaum, James (Jim).

In: Archives of Ophthalmology, Vol. 106, No. 8, 1988, p. 1116-1120.

Research output: Contribution to journalArticle

@article{00e9ea3304b443fb8879e7d6895447cd,
title = "Prostaglandin-Independent Inhibition of Ocular Vascular Permeability by a Platelet-Activating Factor Antagonist",
abstract = "Platelet-activating factor (PAF), a lipid mediator of inflammation, may markedly increase vascular permeability. We assessed the ability of the PAF antagonist SRI 63-441 to inhibit ocular vascular permeability induced by the intravenous injection of endotoxin or anterior chamber paracentesis. The PAF antagonist SRI 63-441 significantly blocked ocular vascular permeability following either intravenous endotoxin or anterior chamber paracentesis as determined by the reduction in accumulation of 70 000-molecularweight fluorescein isothiocyanate—conjugated dextran or serum proteins into the anterior chamber. SRI 63-441 did not reduce increases in aqueous humor prostaglandin E2 levels. The efficacy of the PAF antagonist was additive in combination with either topical indomethacin or topical corticosteroid. Combined therapy almost completely prevented increases in ocular vascular permeability. These data support the conclusion that multiple mediators contribute to ocular vascular permeability and that combinations of pharmacologic agents may be superior to a single drug.",
author = "Rubin, {Richard M.} and Samples, {John R.} and Rosenbaum, {James (Jim)}",
year = "1988",
doi = "10.1001/archopht.1988.01060140272040",
language = "English (US)",
volume = "106",
pages = "1116--1120",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Prostaglandin-Independent Inhibition of Ocular Vascular Permeability by a Platelet-Activating Factor Antagonist

AU - Rubin, Richard M.

AU - Samples, John R.

AU - Rosenbaum, James (Jim)

PY - 1988

Y1 - 1988

N2 - Platelet-activating factor (PAF), a lipid mediator of inflammation, may markedly increase vascular permeability. We assessed the ability of the PAF antagonist SRI 63-441 to inhibit ocular vascular permeability induced by the intravenous injection of endotoxin or anterior chamber paracentesis. The PAF antagonist SRI 63-441 significantly blocked ocular vascular permeability following either intravenous endotoxin or anterior chamber paracentesis as determined by the reduction in accumulation of 70 000-molecularweight fluorescein isothiocyanate—conjugated dextran or serum proteins into the anterior chamber. SRI 63-441 did not reduce increases in aqueous humor prostaglandin E2 levels. The efficacy of the PAF antagonist was additive in combination with either topical indomethacin or topical corticosteroid. Combined therapy almost completely prevented increases in ocular vascular permeability. These data support the conclusion that multiple mediators contribute to ocular vascular permeability and that combinations of pharmacologic agents may be superior to a single drug.

AB - Platelet-activating factor (PAF), a lipid mediator of inflammation, may markedly increase vascular permeability. We assessed the ability of the PAF antagonist SRI 63-441 to inhibit ocular vascular permeability induced by the intravenous injection of endotoxin or anterior chamber paracentesis. The PAF antagonist SRI 63-441 significantly blocked ocular vascular permeability following either intravenous endotoxin or anterior chamber paracentesis as determined by the reduction in accumulation of 70 000-molecularweight fluorescein isothiocyanate—conjugated dextran or serum proteins into the anterior chamber. SRI 63-441 did not reduce increases in aqueous humor prostaglandin E2 levels. The efficacy of the PAF antagonist was additive in combination with either topical indomethacin or topical corticosteroid. Combined therapy almost completely prevented increases in ocular vascular permeability. These data support the conclusion that multiple mediators contribute to ocular vascular permeability and that combinations of pharmacologic agents may be superior to a single drug.

UR - http://www.scopus.com/inward/record.url?scp=0023741542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023741542&partnerID=8YFLogxK

U2 - 10.1001/archopht.1988.01060140272040

DO - 10.1001/archopht.1988.01060140272040

M3 - Article

C2 - 3261165

AN - SCOPUS:0023741542

VL - 106

SP - 1116

EP - 1120

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 8

ER -